NCT02825797View on ClinicalTrials.gov

3BNC117 and 10-1074 in HIV-infected Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 1, 2018

Study Completion Date

August 15, 2018

Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRUG

3BNC117

Intravenous infusion of 3BNC117

DRUG

10-1074

Intravenous infusion of 10-1074

OTHER

Analytical treatment interruption

Analytical treatment interruption

DRUG

Placebo

Intravenous infusion of placebo (sterile saline)

Trial Locations (2)

10065

The Rockefeller University, New York

Unknown

University Hospital of Cologne, Cologne

All Listed Sponsors
collaborator

University Hospital of Cologne

OTHER

lead

Rockefeller University

OTHER

NCT02825797 - 3BNC117 and 10-1074 in HIV-infected Individuals | Biotech Hunter | Biotech Hunter